BC Week In Review | Feb 24, 2014
Clinical News

CardioPET: Phase II data

An open-label, Belgian Phase II trial in 15 CAD patients showed that CardioPET was well tolerated. FluoroPharma said image quality was "excellent" and image time as early as 3 minutes post-injection. In the trial, CardioPET...
BC Week In Review | May 23, 2011
Company News

Commercial E Waste Management, FluoroPharma deal

FluoroPharma completed its reverse merger with Commercial E Waste Management to form FluoroPharma Medical Inc. (OTCBB:CEWM). Under the deal, FluoroPharma Inc. shareholders received about 13.9 million FluoroPharma Medical shares and 661,617 warrants to purchase shares...
BC Week In Review | Sep 15, 2008
Clinical News

FluoroPharma preclinical data

In human prostate tumor cell lines, CardioPET had high uptakes that increased as a function of time. At 30, 60 and 90 minutes, CardioPET uptake increased 350%, 600% and 700% compared with control, respectively. CardioPET...
BC Week In Review | Oct 2, 2006
Clinical News

CardioPET: Phase I started

FluoroPharma began an open-label, U.S. Phase I trial in 18 healthy volunteers. FluoroPharma Inc. , Boston, Mass.   Product: CardioPET   Business: Diagnostic   Molecular target: Not applicable   Description: Positron emission tomography (PET) imaging agent...
Items per page:
1 - 4 of 4